SPAC24B11.14 Antibody

What is SPAC24B11.14 Antibody and what are its key specifications?

SPAC24B11.14 Antibody (Code: CSB-PA891582XA01SXV) is designed for detecting the SPAC24B11.14 protein in Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast . This antibody corresponds to UniProt accession number Q9UR21 and is available in both 2ml and 0.1ml sizes. When selecting this antibody, it's essential to verify whether it's a monoclonal or polyclonal preparation, as this affects its applications and specificity profiles.

Research antibodies require thorough validation before use, as the responsibility for ensuring they are fit for purpose rests with the researcher . Before ordering, confirm the antibody has been validated for your specific application and review available validation data.

How should I validate SPAC24B11.14 Antibody for my S. pombe research?

Validation of SPAC24B11.14 Antibody should follow a systematic approach:

• Checking existing validation data: Review the product sheet and literature for existing validation in your application of interest .

• Application-specific validation: Test the antibody in the specific application you intend to use it for (WB, IP, IF, etc.) as antibody performance varies substantially between techniques .

• Validation in knockout/knockdown models: The gold standard for antibody validation is testing in knockout or knockdown S. pombe strains where the SPAC24B11.14 gene has been deleted or silenced . Absence of signal in these models strongly supports specificity.

• Comparison with established antibodies: If other antibodies against SPAC24B11.14 exist, compare their performance .

• Independent method verification: Verify your findings using orthogonal techniques that don't rely on antibodies .

Remember that validation needs to be context-specific. An antibody that works for Western blotting may not be suitable for immunoprecipitation due to differences in protein conformation between applications .

What experimental applications is SPAC24B11.14 Antibody suitable for?

The suitability of SPAC24B11.14 Antibody for specific applications should be verified through vendor documentation and validation experiments. Common applications include:

Always run appropriate controls with each experiment, regardless of the application .

What are the common pitfalls when using SPAC24B11.14 Antibody?

Several common pitfalls may compromise research with SPAC24B11.14 Antibody:

• Inadequate validation: Failure to verify specificity in your experimental system and application .

• Batch-to-batch variation: Different batches may show variability in performance and specificity. Record batch numbers and revalidate when switching batches .

• Unsuitable application: Using the antibody for applications it hasn't been validated for .

• Insufficient optimization: Failing to optimize antibody concentration, incubation time, and buffer conditions .

• Improper controls: Not including positive and negative controls in each experiment .

• Overlooking cross-reactivity: Neglecting potential cross-reactivity with similar proteins in S. pombe .

• Ignoring epitope accessibility: Post-translational modifications or protein-protein interactions may mask the epitope .

To avoid these issues, comprehensive validation, careful optimization, and thorough documentation are essential.

How does epitope recognition of SPAC24B11.14 Antibody affect experimental design?

The epitope recognized by SPAC24B11.14 Antibody significantly influences experimental design and interpretation:

For accurate experimental design, researchers should determine whether the antibody recognizes a linear or conformational epitope . This information might be available from the manufacturer or may require experimental determination.

Linear epitopes are typically more resistant to denaturation, making the antibody suitable for techniques like Western blotting where proteins are denatured . Conformational epitopes require the protein to maintain its native folding, making them better for immunoprecipitation or flow cytometry applications .

The location of the epitope within the SPAC24B11.14 protein is also crucial. If targeting specific domains or isoforms is important, the epitope location must be precisely known . For example, if the antibody recognizes an epitope in a domain that undergoes alternative splicing or post-translational modification, certain variants might not be detected.

When studying protein-protein interactions involving SPAC24B11.14, researchers must consider whether the antibody's epitope overlaps with interaction sites. If so, the antibody might disrupt interactions or fail to recognize the protein when it's in complex with its partners .

What is the optimal validation strategy for SPAC24B11.14 Antibody in comparative proteomic studies?

For comparative proteomic studies involving SPAC24B11.14 Antibody, a comprehensive validation strategy is recommended:

Five-pillar validation approach: Following the consensus recommendations for antibody validation, implement multiple complementary validation methods :

• Genetic strategies: Use SPAC24B11.14 knockout or knockdown S. pombe strains as negative controls. Signal absence in these strains provides strong evidence of specificity .

• Independent antibody approach: Compare results with a second antibody targeting a different epitope of SPAC24B11.14. Concordant signals support specificity .

• Orthogonal strategies: Correlate antibody-based detection with mass spectrometry or RNA-seq data for SPAC24B11.14 expression .

• Expression of tagged proteins: Express epitope-tagged SPAC24B11.14 and verify co-localization with antibody signal .

• Immunocapture-MS validation: Perform immunoprecipitation with SPAC24B11.14 Antibody followed by mass spectrometry analysis. The top three peptide sequences should correspond to SPAC24B11.14 .

Researchers should document all validation steps methodically and include all relevant controls in experimental designs to ensure reproducibility and reliability of comparative proteomic data.

How can I troubleshoot inconsistent results with SPAC24B11.14 Antibody across different S. pombe strains?

Inconsistent results with SPAC24B11.14 Antibody across S. pombe strains may stem from multiple factors:

• Strain-specific protein expression levels: Different S. pombe strains may express SPAC24B11.14 at varying levels. Quantify transcript levels via RT-qPCR to determine if inconsistencies reflect actual expression differences .

• Protein variants: Check for strain-specific isoforms or post-translational modifications that might affect epitope recognition . Compare genomic sequences of the SPAC24B11.14 locus across strains.

• Experimental conditions optimization:

  • Adjust antibody concentration: Test a range of dilutions (1:100 to 1:10,000)

  • Modify incubation times and temperatures

  • Try different blocking agents to reduce background

  • Test various antigen retrieval methods if applicable

• Sample preparation variables: Ensure consistent protein extraction methods across strains. Different lysis conditions can affect protein solubility and epitope exposure .

• Antibody batch variation: Verify you're using the same batch across experiments, or validate new batches against old ones .

• Cross-reactivity analysis: Perform peptide competition assays to verify specificity in each strain background .

• Independent verification: Use orthogonal detection methods (e.g., mass spectrometry) to confirm protein presence and abundance in different strains .

Documentation of all variables is essential for troubleshooting and should include detailed protocols, antibody batches, and exact strain identifiers.

What are the best practices for reporting SPAC24B11.14 Antibody use in scientific publications?

Comprehensive reporting of SPAC24B11.14 Antibody use is crucial for experimental reproducibility:

Essential information to include:

• Complete antibody identification:

  • Full name: SPAC24B11.14 Antibody

  • Catalog number: CSB-PA891582XA01SXV

  • Supplier/vendor

  • Clone number (for monoclonal antibodies)

  • Host species

  • Whether it's monoclonal or polyclonal

• Validation information:

  • Validation methods used (genetic, orthogonal, independent antibody, etc.)

  • Controls employed (positive, negative, isotype)

  • Evidence of specificity for intended application

  • Include validation data in supplementary information if using the antibody in a new application

• Experimental details:

  • Working concentration or dilution

  • Incubation conditions (time, temperature)

  • Buffer composition

  • Blocking reagents

  • Detection methods

  • Batch number (especially if batch variation is observed)

• Application linkage: Clearly link which applications the antibody was used for in your study .

• Quantitative methods: Describe all quantification methods in detail, including software used and analysis parameters .

How does antibody-antigen binding prediction apply to SPAC24B11.14 Antibody research?

Advanced computational approaches can enhance SPAC24B11.14 Antibody research:

Machine learning models are increasingly being used to predict antibody-antigen binding, which could be valuable for SPAC24B11.14 research. These models analyze many-to-many relationships between antibodies and antigens, but face challenges with out-of-distribution prediction when test antibodies and antigens aren't represented in training data .

Recent research has developed active learning strategies for antibody-antigen binding prediction in library-on-library settings. The best algorithms have shown the ability to reduce the number of required antigen mutant variants by up to 35% and accelerate the learning process by 28 steps compared to random baseline approaches .

For S. pombe researchers, these computational approaches could be particularly valuable when:

• Designing new antibodies against different SPAC24B11.14 epitopes

• Predicting cross-reactivity with similar proteins in S. pombe

• Optimizing experimental conditions based on predicted binding properties

• Investigating the effects of mutations in SPAC24B11.14 on antibody recognition

The PLAbDab (Patent and Literature Antibody Database) contains over 150,000 paired antibody sequences and 3D structural models that could be used to inform SPAC24B11.14 antibody research through sequence or structure-based queries .

What controls are essential when using SPAC24B11.14 Antibody in S. pombe research?

Rigorous controls are fundamental for reliable research with SPAC24B11.14 Antibody:

Essential controls include:

• Negative controls:

  • SPAC24B11.14 knockout or knockdown strains

  • Isotype control antibody (same species and isotype, but irrelevant specificity)

  • Secondary antibody only (to detect non-specific binding)

  • Peptide competition assay (pre-incubation with immunizing peptide should abolish signal)

• Positive controls:

  • Strains known to express SPAC24B11.14 at high levels

  • Recombinant SPAC24B11.14 protein (if available)

  • Tagged SPAC24B11.14 expression system

• Technical controls:

  • Loading controls for Western blots (e.g., housekeeping proteins)

  • Standard curves for quantitative assays

  • Concentration gradients to determine optimal antibody amounts

  • Multiple exposure times to ensure linearity of signal

• Biological controls:

  • Multiple S. pombe strains to account for strain variation

  • Biological replicates to assess reproducibility

  • Samples from different growth conditions where SPAC24B11.14 expression is expected to vary

Documentation of all controls is essential for publication and should include methods, reagents, and quantitative results.

How can I optimize immunoprecipitation protocols specifically for SPAC24B11.14 Antibody?

Optimizing immunoprecipitation (IP) with SPAC24B11.14 Antibody requires systematic refinement:

Step-by-step optimization strategy:

• Lysis buffer optimization:

  • Test different buffer compositions (RIPA, NP-40, Triton X-100)

  • Adjust salt concentration (150-500 mM)

  • Include appropriate protease/phosphatase inhibitors

  • Consider detergent concentration affects on protein-protein interactions

• Antibody binding conditions:

  • Determine optimal antibody amount (typically 1-5 μg per IP)

  • Test different incubation times (2h vs. overnight)

  • Compare incubation temperatures (4°C vs. room temperature)

• Capture system selection:

  • Compare protein A/G beads vs. magnetic beads

  • Test pre-clearing steps to reduce background

  • Optimize bead amount and incubation time

• Washing stringency balancing:

  • Develop washing protocol that removes non-specific binding without disrupting specific interactions

  • Test increasing salt concentrations in wash buffers

  • Consider detergent types and concentrations

• Elution method comparison:

  • Compare gentle (native) vs. harsh (denaturing) elution methods

  • Test specific peptide elution for native IP

• Verification:

  • Confirm successful IP by Western blot

  • Identify co-immunoprecipitated proteins by mass spectrometry

  • Use orthogonal methods to verify interactions

Document all optimization steps and results to establish a reproducible protocol for SPAC24B11.14 immunoprecipitation.

What are the recommended approaches for quantitative analysis of SPAC24B11.14 expression using this antibody?

Quantitative analysis of SPAC24B11.14 expression requires standardized approaches:

Quantitative Western blotting:

• Use a standard curve of recombinant SPAC24B11.14 protein (if available)

• Include multiple technical and biological replicates

• Ensure signal is in the linear range of detection

• Use appropriate loading controls (e.g., tubulin, actin)

• Employ image analysis software with background subtraction

• Report band intensities normalized to loading controls

Immunofluorescence quantification:

• Standardize image acquisition parameters (exposure time, gain)

• Include control samples in each experiment

• Capture multiple fields of view per sample

• Use automated analysis software to minimize bias

• Report both intensity and distribution metrics

• Include appropriate statistical analysis

Flow cytometry analysis:

• Use fluorescence minus one (FMO) controls

• Include isotype controls

• Establish appropriate gating strategy

• Report mean fluorescence intensity (MFI)

• Include sufficient cell numbers for robust statistics

• Compare to other quantification methods when possible

ELISA or other immunoassays:

• Develop standard curves using recombinant protein

• Optimize antibody concentration and incubation conditions

• Include controls for non-specific binding

• Report absolute concentrations when possible

• Document assay sensitivity and dynamic range

All quantitative analyses should include appropriate statistical methods and clearly stated sample sizes.